非小细胞肺癌分子靶向EGFR-TKI治疗敏感性与治疗耐受性预测筛选的分子显像研究现状及进展

发布时间：2018-08-19 17:01

【摘要】：肺癌80%以上为非小细胞肺癌(non-small cell lung cancer,NSCLC),表皮生长因子受体(epidermal growth factor receptor,EGFR)介导的信号通路与NSCLC发生发展密切相关。针对EGFR的小分子EGFR赖氨酸激酶抑制剂(EGFR-tyrosine kinase inhibitor,EGFR-TKI)被应用于NSCLC的临床治疗,正电子发射计算机断层显像(positron emission tomography/computed tomgraphy,PET/CT)能够无创地对NSCLC患者全身EGFR表达及突变状况进行连续动态监测。~(18)F-FDG PET/CT显像对于EGFR活化突变、EGFR-TKI治疗疗效具有预测价值,并且能够在体直接观察到药物与全身肿瘤病灶EGFR靶向结合的具体情况,通过治疗前后的PET-CT显像,实现治疗前高敏人群筛选和治疗全过程的动态监测、治疗策略指导,对实现NSCLC的EGFR-TKI精准治疗至关重要。
[Abstract]:More than 80% of lung cancer is non-small cell lung cancer.Epidermal growth factor receptor (epidermal growth factor receptor EGFR-mediated signaling pathway is closely related to the development of NSCLC. EGFR-tyrosine kinase inhibitor EGFR-TKI targeting EGFR has been used in the clinical treatment of NSCLC. Positron emission computed tomography (positron emission tomography/computed tomgraph PET / CT) was able to noninvasive dynamic monitoring of EGFR expression and mutation status in the whole body of NSCLC patients. ~ (18) F-FDG PET/CT imaging could predict the therapeutic effect of EGFR activated mutation and EGFR-TKI. We can directly observe the specific situation of EGFR targeting combination of drug and tumor focus in vivo. Through PET-CT imaging before and after treatment, we can realize the screening of Gao Min population before and after treatment, the dynamic monitoring of the whole course of treatment, and the guidance of treatment strategy. It is very important to achieve accurate EGFR-TKI therapy for NSCLC.
【作者单位】：天津医科大学肿瘤医院分子影像及核医学诊疗科国家肿瘤临床医学研究中心天津市肿瘤防治重点实验室;
【基金】：天津市自然科学基金(No.17JCYBJC25100) 天津医科大学肿瘤医院人才启动基金(No.B1605)资助~~
【分类号】：R734.2

【相似文献】